A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis who have previously failed one or more DMARDs

Trial Profile

A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis who have previously failed one or more DMARDs

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2013

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Nov 2013 The extension study has been discontinued as the sponsor is no longer developing IV ofatumumab for rheumatoid arthritis, according to the Clinicaltrials.gov record.
    • 28 Jul 2011 New source identified and integrated (European ClinicalTrials Database).
    • 21 Jan 2009 GlaxoSmithKline reported as trial sponsor, and patient inclusions updated from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top